CN106109482A - A kind of glycol group rare ginsenoside compositions with anti-tumor activity - Google Patents
A kind of glycol group rare ginsenoside compositions with anti-tumor activity Download PDFInfo
- Publication number
- CN106109482A CN106109482A CN201610616138.3A CN201610616138A CN106109482A CN 106109482 A CN106109482 A CN 106109482A CN 201610616138 A CN201610616138 A CN 201610616138A CN 106109482 A CN106109482 A CN 106109482A
- Authority
- CN
- China
- Prior art keywords
- ginsenoside
- compositions
- weight portion
- rare
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
Abstract
The present invention provides a kind of glycol group rare ginsenoside compositions with anti-tumor activity.In this rare ginsenoside compositions, in terms of total ginsenoside 100 weight portion in this rare ginsenoside compositions, comprise: ginsenoside Rg 5 5～90 weight portion, ginsenoside Rg3 5～90 weight portion, and ginsenoside Rk1 5～90 weight portion.
Description
Technical field
The present invention relates to biomedicine field, be specifically related to comprise ginsenoside Rg 5, the antitumor that has of Rg3 and Rk1 is lived
The rare ginsenoside compositions of property.
Background technology
Cancer is the sick kind of the second largest threat mankind being only second to cerebrovascular disease.The number of the infected of China's cancer surpasses every year
Cross 3,000,000 people, and the sickness rate of pulmonary carcinoma, breast carcinoma, the esophageal carcinoma increases year by year, wherein the sickness rate annual rate of growth of pulmonary carcinoma
26.8%, breast cancer incidence annual rate of growth 6.8%.Since 30 years, the mortality rate of breast carcinoma rises 96%, the death of pulmonary carcinoma
Rate surges 465%, and the prevention and control of cancer work of China is very urgent and the situation is tense.
The most clinical conventional cancer treatment method has excision, radiotherapy, chemotherapy etc., and these means have obvious
Limitation.Wherein, the health ability to bear of excision patient to be considered, the difficulty of operative site, excision effect etc. are in many ways
Face factor, has quite a few patient body condition to have limitation (age, merging other diseases etc.) to be not suitable for operative treatment.Put
Treating the bone marrow depression that typically can produce local, the generation of radiation pericarditis the most substantially increases, in addition radiotherapy position surrounding tissue
Damage relatively big, also have sizable a part of patient's discomfort to be fit to do radiotherapy.Chemotherapy is the most the more commonly used treatment of cancer hands
Section, such as, treat conventional medicine gefitinib (trade name: Iressa) and angstrom replace Buddhist nun gram, having one nonsmall-cell lung cancer
Fixed therapeutical effect, but side effect is the most obvious, modal adverse effect have diarrhoea, erythra, pruritus, vomiting,
Alopecia etc., and incidence rate is higher, patient occurs leukocyte drastically to decline while chemotherapy, and immune system destruction is more serious,
Weight in patients declines, anorexia, causes overall curative effect undesirable.Therefore, side effect definite for antitumous effect clinically
Little oral or injection class medicine demand is very big.
A lot of research worker are all gathered in sight on Chinese medicine extract or plant extract, wherein paclitaxel and Radix Ginseng soap
Glycosides is the representational two kinds of active ingredient of Chinese herbs of comparison.Paclitaxel derives from the branch of Ramulus et folium taxi cuspidatae, extracted, isolated and purified
Arriving, owing to Chinese yew is set to one-level rare endangered plants by China in 1994, resource regeneration is extremely slow, thus purple
The limited source of China fir alcohol, and therapeutic effect is limited.Ginsenoside can pass through Araliaceae Radix Ginseng, Radix Notoginseng, Panax pseudoginseng Wall., Jiang Zhuansan
Seven, Rhizoma Panacis Japonici etc. extract and obtain.Ginsenoside can be divided into glycol group ginsenoside and triol group ginsenoside, wherein, glycol
Group ginsenoside includes that Rb1, Rb2, Rb3, Rc, Rd, Rg3, Rh2 etc., triol group ginsenoside include Re, Rg1, Rg2, Rh1 etc..
It has been reported that some ginsenosides are individually to having antitumor action in domestic literature, but, about how by spy
The ginsenoside monomer determining kind is combined, and but rarely has report obtaining more preferable antitumous effect.
Summary of the invention
It is an object of the invention to provide a kind of new rare ginsenoside compositions with synergistic antitumor effect.This
Outward, another object of the present invention is to the purposes providing above-mentioned rare ginsenoside compositions in preparing antitumor drug.
The present inventor finds through further investigation, and the special ratios compositions of rare ginsenoside Rg5, Rg3 and Rk1 has
Wide spectrum and the significant antitumor action of potentiation, thus complete the present invention.
That is, the present invention is as follows.
1. there is a rare ginsenoside compositions for anti-tumor activity, wherein, with this rare ginsenoside compositions
In total ginsenoside 100 weight portion meter, this rare ginsenoside compositions comprises:
Ginsenoside Rg 5 5～90 weight portion,
Ginsenoside Rg3 5～90 weight portion, and
Ginsenoside Rk1 5～90 weight portion.
2. according to the rare ginsenoside compositions described in item 1, wherein, this rare ginsenoside compositions comprises:
Ginsenoside Rg 5 20～40 weight portion,
Ginsenoside Rg3 20～40 weight portion,
Ginsenoside Rk1 20～40 weight portion.
3. according to the rare ginsenoside compositions described in item 1 or 2, wherein, with in this rare ginsenoside compositions
Total ginsenoside 100 weight portion meter, described ginsenoside Rg 5, Rg3 and Rk1 add up to more than 20 weight portions.
4. according to item 1～3 arbitrarily according to any one of rare ginsenoside compositions, wherein, relative to this rare people
Total amount 100 weight portion of ginseng astragalin composition, described ginsenoside Rg 5, Rg3 and Rk1 add up to more than 1 weight portion.
5. according to the purposes in preparing antitumor drug of the rare ginsenoside compositions according to any one of item 1～4.
6. according to the purposes described in item 5, wherein, described antitumor drug is peroral dosage form or injection type.
7. according to the purposes according to any one of item 5～6, wherein, described tumor is pulmonary carcinoma, colon cancer, gastric cancer or mammary gland
Cancer.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention will be described in detail.In the case of conflict free, this specification
In scientific terminology there is the implication that those skilled in the art are generally understood that, if any conflict should be with the definition in this specification
Accurate.
First, in an aspect, the present invention provides a kind of rare ginsenoside compositions (this with anti-tumor activity
The rare ginsenoside compositions of invention), wherein, with total ginsenoside 100 weight portion in this rare ginsenoside compositions
Meter, this rare ginsenoside compositions comprises:
Ginsenoside Rg 5 5～90 weight portion,
Ginsenoside Rg3 5～90 weight portion,
Ginsenoside Rk1 5～90 weight portion.
In this manual, ginsenoside Rg3 refers to the compound described in following chemical formula 1.
[chemical formula 1]
20 (R)-ginsenoside Rg3s
In this manual, ginsenoside Rg 5 refers to the compound described in following chemical formula 2.
[chemical formula 2]
Ginsenoside Rg 5
In this manual, ginsenoside Rk1 refers to the compound described in following chemical formula 3.
[chemical formula 3]
Ginsenoside Rk1
Above-mentioned ginsenoside Rg 5, the known compound of Rg3 and Rk1, can use methods known in the art system
Standby.Such as ginsenoside Rg 5 can be manufactured by thermal cracking ginsenoside Rb1, and ginsenoside Rg3 can pass through acid hydrolysis people
Ginseng saponin Rb1 manufactures, and ginsenoside Rk1 can be manufactured by ginsenoside Rb1.Above-mentioned ginsenoside Rg 5, Rg3 and Rk1
Can be purified by preparation scale HPLC.
The inventors discovered that, during by above-mentioned three kinds of rare ginsenosides with given dose, special ratios combination, gained combines
Thing has wide spectrum and the significant antitumor action of potentiation.
Specifically, the rare ginsenoside compositions of the present invention preferably comprises: ginsenoside Rg 5 10～80 weight portion,
Ginsenoside Rg3 10～80 weight portion, and ginsenoside Rk1 10～80 weight portion.The rare ginsenoside group of the present invention
Compound more preferably comprises: ginsenoside Rg 5 20～40 weight portion, ginsenoside Rg3 20～40 weight portion, and ginsenoside
Rk1 20～40 weight portion.
Described ginsenoside Rg 5, Rg3 and Rk1 are rare ginsenoside, its content in natural ginseng extract low or
Do not exist.But in the rare ginsenoside compositions of the present invention, described ginsenoside Rg 5, Rg3 and Rk1 content height.Preferably
Ground, relative to total amount 100 weight portion of the rare ginsenoside compositions of the present invention, described ginsenoside Rg 5, Rg3 and Rk1 close
It is calculated as more than 1 weight portion, more than more preferably 2 weight portions, more than more preferably 5 weight portions, more than more preferably 10 weight portions.
Moreover it is preferred that in terms of total ginsenoside 100 weight portion in the rare ginsenoside compositions of the present invention, described Radix Ginseng soap
Glycosides Rg5, Rg3 and Rk1 add up to more than 20 weight portions, be preferably more than 50 weight portions, more than more preferably 60 weight portions, more excellent
Elect as more than more than more than 70 weight portions, more preferably 80 weight portions, more preferably 90 weight portions, more preferably 95 weight portions with
On.
Here, the content of described total ginsenoside can use vanillin method to measure, and described ginsenoside Rg 5 can use
HPLC method measures, and described ginsenoside Rg3 can use HPLC method to measure, and described ginsenoside Rk1 can use HPLC method to survey
Fixed.
The rare ginsenoside compositions of the present invention can also comprise adjuvant.Rare ginsenoside group for the present invention
Adjuvant in compound, is not particularly limited, such as, the art can be used to be generally used for the adjuvant of medicine or health product.
Secondly, in one aspect of the method, the present invention provides the rare ginsenoside compositions of the invention described above to resist in preparation
Purposes in tumour medicine.
Just it has been observed that the rare ginsenoside compositions of the present invention has wide spectrum and the significant antitumor action of potentiation.
Here, " antitumor " includes killing tumor cell, promoting apoptosis of tumor cells, suppression tumor growth, suppression tumor
Shift, suppress blood capillary proliferation, improve tumor prognosis or prevent tumor recurrence etc..These tumors include such as: the cerebral tumor, head
Adenocarcinoma, oral cancer, salivary-gland carcinoma, Sublingual adenocarcinoma, carcinoma of parotid gland, tumor of nasal cavity, secondary nose under cervical region cancer, neck cancer, carcinoma of palate, upper carcinoma of palate, palate
Chamber cancer, larynx cancer, esophageal carcinoma, pulmonary carcinoma, breast carcinoma, cancer of pancreas (including pancreatic ductal carcinoma), gastric cancer, cancer of bile ducts, carcinoma of small intestine or 12 refer to
Intestinal cancer, colorectal cancer, bladder cancer, renal carcinoma (including renal cell carcinoma), hepatocarcinoma, carcinoma of prostate, uterus carcinoma (include cervical cancer, uterus
Body cancer), ovarian cancer, thyroid carcinoma, pharynx cancer, sarcoma, malignant lymphoma, leukemia, lymphoma, skin carcinoma and melanoma
Deng.
Antitumous effect can be diagnosed by the pathological tissue of the observed result of such as X-ray photograph, CT etc. and biopsy or swollen
The values of tumor markers etc. confirm.
The dosage form of described antitumor drug is not particularly limited, such as, can be peroral dosage form or injection type.Described
Peroral dosage form can be liquid dosage form, it is also possible to be solid dosage forms.
When preparing solid preparation for oral administration, can add in principal agent excipient and the binding agent depended on the needs,
After disintegrating agent, lubricant, coloring agent, correctives etc., conventionally make tablet, coated tablet, granule, granula subtilis,
Powder, capsule etc..
As excipient, can use such as lactose, corn starch, white sugar, glucose, Sorbitol, crystalline cellulose, two
Silicon oxide etc.；As binding agent, such as polyvinyl alcohol, ethyl cellulose, methylcellulose, arabic gum, hydroxyl third can be used
Base cellulose, HYDROXY PROPYL METHYLCELLULOSE etc.；As lubricant, such as magnesium stearate, Talcum, silicon dioxide etc. can be used；
As coloring agent, the coloring agent allowing to add in medicine can be used；As correctives, cocoa powder, Mentholum, fragrance can be used
Acid, Oleum menthae, Borneolum Syntheticum, Cortex cinnamomi japonici powder.It is of course also possible on above-mentioned tablet, granule be coated with sugar-coat, gelatin clothing and other
Necessary coat.
When preparing injection, pH adjusting agent, buffer agent, outstanding auxiliary agent, solubilizing agent, steady can be added as required in principal agent
Determine agent, isotonic agent, preservative etc., make vein, subcutaneous, intramuscular injection agent according still further to conventional method.At this time it is also possible to according to
Need, utilize conventional method to make lyophilization thing.
As outstanding auxiliary agent, such as methylcellulose, Tween 80, hydroxy ethyl cellulose, arabic gum, Radix astragali tree can be enumerated
Rubber powder, sodium carboxymethyl cellulose, polyoxyethylene sorbitol mono laurate salt etc..
As solubilizing agent, such as polyoxyethylene hydrogenated castor oil, Tween 80, nicotiamide, polyoxyethylene can be enumerated
Sugar alcohol mono laurate salt, Polyethylene Glycol, Castor Oil Fatty Acid ethyl ester etc..
It addition, as stabilizer, such as sodium sulfite, sodium metasulfite etc. can be enumerated；As preservative, can enumerate such as
Methyl parahydroxybenzoate, ethylparaben, sorbic acid, phenol, cresol, chlorocresol etc..
The mechanism of action for described antitumor drug is not particularly limited, can be such as suppress tumor cell proliferation,
Antitumor cell transfer, promotion apoptosis of tumor cells, suppression tumor angiogenesis and/or the immunity of raising body.
Additionally, in another aspect, the present invention also provides for the method for the tumor in a kind for the treatment of target, and it includes to described
Object uses the step of the rare ginsenoside compositions of the present invention.
Here, described object can be mammal, such as, can be people, rat, rabbit, sheep, pig, cattle, cat, Canis familiaris L., monkey etc.,
It is preferably people.
The rare ginsenoside compositions of the present invention, can be administered orally or parenteral use.Amount of application is because of symptom degree, patient
Age, sex, body weight, sensitivity differences, application process, Dressing date, administration interval, the character of pharmaceutical preparation, effective ingredient
Kind etc. and different, without particular restriction: but generally adult (body weight 60Kg) every day 1～3000mg, preferably 10～1000mg, more
Preferably 100～500mg, above-mentioned amount of application generally can every bu 1～use for 3 times.Preferably dosage is 300mg every day.
Embodiment
Example given below, is for the ease of understanding the present invention, and limits the right of the present invention never in any form
The scope required.
Embodiment 1
The respectively aqueous solution of Rg5, Rg3 and Rk1 of compound concentration 125ug/mL, call it as respectively Rg5-1, Rg3-1 and
Rk1-1。
By the aqueous solution comprising Rg5, Rg3 and Rk1 of Rg5:Rg3:Rk1=10:75:15 preparation total concentration 125ug/mL,
Call it as compositions 1.
Use above-mentioned Rg5-1, Rg3-1, Rk1-1 and compositions 1, and lung carcinoma cell Nci-H460, colon cancer cell
Caco-2, stomach cancer cell SGC-7901, breast cancer cell MCF-7 these four cancerous cell carry out inhibition of cancer cell experiment respectively.Tool
Body step is as follows:
(1) human estrogen acceptor positive breast cancer cells strain MCF-7, human lung carcinoma cell line NCI-H460, gastric carcinoma cells
Strain SGC-7901, human colon cancer cell strain Caco-2, with RPMI 1640 cell culture fluid, these four cell is attached cell.
Frozen Cell sap is centrifuged 5min at 1500rpm, abandons supernatant, add fresh cell medium, blow even, be added into culture dish
In, to put into containing 5%C02, in the biochemical cultivation case of 37 DEG C, treat that cell attachment grows 24h or 48h, cell number reaches 80%
During left and right, add PBS and wash 2-3 time, add 3mL pancreatin, digest 1-2min, after treating cell rounding, addition etc. at 37 DEG C
Volume cells training liquid terminates digestion, and is blown down bottom culture dish by cell.Collect Cell sap, centrifugal, abandon supernatant, add one
Fixed culture fluid, blows even, and Cell sap is added two 25cm respectively.In culture dish, continue to cultivate.
(2) when growth of cancer cells to about 80%, add PBS and wash 2-3 time, add 3mL pancreatin, 37 DEG C of digestion
1-2min, after treating cell rounding, adds equal-volume cell culture fluid and terminates digestion, and blown down bottom culture dish by cell
Come.Collect Cell sap, centrifugal, abandon supernatant, add certain culture fluid, blow even, take about 50 μ L and be added on cell counting count board,
Count on inverted microscope.Cell density=(four big lattice cell number sums) × 104/4.Adjust cell density to (7-10) ×
104/ mL, by cell inoculation with 96 orifice plates, every hole adds 0.1mL, puts into 24h in incubator.
(3) after 24h, sucking the culture fluid in each hole, add saponin sample, each concentration arranges 5 multiple holes.Then put
Entering and hatch 48h in incubator, after 48h, suck old culture fluid in hole, every hole is sequentially added into 100 μ L culture fluid and 50 μ L MTT are molten
Liquid, shakes up, and puts into and hatches 4h in incubator, sucking-off mixed liquor after 4h, adds 150 μ L DMSO to dissolve purple crystals first a ceremonial jade-ladle, used in libation, shake
Swing 10min, put in microplate reader, detect wavelength 570nm, measure the absorbance A in every hole.
(4) suppression ratio=(blank group A-experimental group A) × 100%/blank group.
Above-mentioned Rg5-1, Rg3-1, Rk1-1 and compositions 1 are as shown in table 1 to the suppression ratio of various cancerous cell.
Table 1 Rg5-1, Rg3-1, Rk1-1 and the compositions 1 suppression ratio to various cancerous cell
Embodiment 2
The respectively aqueous solution of Rg5, Rg3 and Rk1 of compound concentration 62.5ug/mL, call it as respectively Rg5-2, Rg3-2 and
Rk1-2。
By the aqueous solution comprising Rg5, Rg3 and Rk1 of Rg5:Rg3:Rk1=30:35:35 preparation total concentration 62.5ug/mL,
Call it as compositions 2.
Above-mentioned Rg5-2, Rg3-2, Rk1-2 and compositions 2 is used to carry out inhibition of cancer cell experiment as in Example 1.
Above-mentioned Rg5-2, Rg3-2, Rk1-2 and compositions 2 are as shown in table 2 to the suppression ratio of various cancerous cell.
Table 2 Rg5-2, Rg3-2, Rk1-2 and the compositions 2 suppression ratio to various cancerous cell
Embodiment 3
The respectively aqueous solution of Rg5, Rg3 and Rk1 of compound concentration 250ug/mL, call it as respectively Rg5-3, Rg3-3 and
Rk1-3。
By the aqueous solution comprising Rg5, Rg3 and Rk1 of Rg5:Rg3:Rk1=70:10:20 preparation total concentration 250ug/mL,
Call it as compositions 3.
Above-mentioned Rg5-3, Rg3-3, Rk1-3 and compositions 3 is used to carry out inhibition of cancer cell experiment as in Example 1.
Above-mentioned Rg5-3, Rg3-3, Rk1-3 and compositions 3 are as shown in table 3 to the suppression ratio of various cancerous cell.
Table 3 Rg5-3, Rg3-3, Rk1-3 and the compositions 3 suppression ratio to various cancerous cell
From the result of above-described embodiment 1～3, compared with Rg5, Rg3 and Rk1 monomer, the compositions of the present invention can
Significantly improve inhibition of cancer cell rate, and by adjusting amount and the ratio of Rg5, Rg3 and Rk1 monomer in compositions, it is possible to obtain more
Good inhibition of cancer cell effect.
Rare ginsenoside compositions tumor-bearing mice subcutaneous to the S180 inhibiting tumor assay of embodiment 4 present invention
Design with reference to Chinese patent bulletin CN101695513B embodiment 8, slightly change.
Experiment material: glycol group rare ginsenoside compositions (prepare according to the ratio in embodiment 1, purity >=
95%), laboratory self-control；Cyclophosphamide (CTX), 200mg/ bottle, Hengrui Medicine Co., Ltd., Jiangsu Prov.'s product.Laboratory animal
And cell line: Kunming mouse, female, body weight 20g-24g, purchased from Xi'an Communications University's Experimental Animal Center.Sarcoma 180
Ascit form (S180), purchased from Shanghai Pharmaceutical Inst., Chinese Academy of Sciences.
Method
Tumor kind preserves and passes on: nothing after the aseptic oncocyte that takes of abdominal cavity tumor-bearing mice, sterilized normal saline (NS) dilution
Bacterium operation is inoculated in normal adult mice abdominal cavity, within every 7 days, passes for 1 generation.
Lotus tumor model production method: putting to death the S180 tumor-bearing mice that abdominal cavity is passed on 7 days, sterile working takes ascites.Sterilizing NS
Dilution ascites adjusts oncocyte concentration to 8 × 106/mL, oncocyte mortality rate < 5%.By sterile working's requirement, oncocyte is hanged
Liquid is inoculated in mouse peritoneal, and 0.2mL/ is only.
Laboratory observation to subcutaneous mice with tumor: 50 mices, the most subcutaneous lotus tumor, it is randomly divided into 5 groups next day, often group 10.
Packet includes: CTX treatment group；Blank group；Glycol group rare ginsenoside compositions basic, normal, high dosage group；Each group all exists
Abdominal cavity lotus tumor plays gastric infusion next day, once a day, is administered 0.1mL/10g every time.CTX is intraperitoneal injection, 30mg/kg,
It is used in conjunction 7 days；The glycol group basic, normal, high dosage of rare ginsenoside compositions is respectively 250mg/kg, 500mg/kg, 1000mg/
Kg, with to dead first 1 day, processes for the 12nd day after subcutaneous lotus tumor.Medication process observation ordinary circumstance.Each batch animal processes
Time, first weighing, place after death takes tumor, thymus, spleen and weighs, and then calculates tumour inhibiting rate, thymus index, index and spleen index.
Statistical procedures: measurement data represents with mean ± standard deviation (x ± s).Use one factor analysis of variance, between group two
Two compare employing q inspection.
Result
Glycol group rare ginsenoside compositions dosage group little, middle and high all can significantly extend S180 mouse growth.Wherein,
Glycol group rare ginsenoside compositions small dose group and middle dosage group tumor-inhibiting action are notable, and the tumor-inhibiting action of high dose is the most aobvious
Write.Glycol group rare ginsenoside group more can promote the rise of thymus index, index and spleen index.The results are shown in Table 4, table 5.Thus may be used
Seeing, glycol group rare ginsenoside compositions has oncotherapy effect.
The table 4 glycol group rare ginsenoside compositions tumor-inhibiting action (n=10, x ± s) to subcutaneous tumor-bearing mice
The impact (n=10, x ± s) on subcutaneous tumor-bearing mice immune organ of the table 5 glycol group rare ginsenoside compositions
Also, it should be noted can implement and on the premise of the inconspicuous purport running counter to the present invention, in this manual
Combination as the arbitrary technical characteristic described by the composition part of a certain technical scheme or technical characteristic can also be suitable for equally
In other technical scheme；Further, can implement and on the premise of the inconspicuous purport running counter to the present invention, as different technologies scheme
The technical characteristic described by composition part between can also be combined in any way, constitute other technical scheme.This
Invention be also contained in above-mentioned in the case of by combination the technical scheme that obtains, and these technical schemes are equivalent to be documented in
In description.
Describe the present invention above by detailed description of the invention and embodiment, but those skilled in the art should manage
Solving, these are not intended to be defined the scope of the present invention, and the scope of the present invention should be determined by claims.
Industrial applicibility
In accordance with the invention it is possible to provide a kind of rare ginsenoside compositions with the notable antitumor action of potentiation.
Claims (7)
1. there is a rare ginsenoside compositions for anti-tumor activity, wherein, with in this rare ginsenoside compositions
Total ginsenoside 100 weight portion meter, this rare ginsenoside compositions comprises:
Ginsenoside Rg 5 5～90 weight portion,
Ginsenoside Rg3 5～90 weight portion,
Ginsenoside Rk1 5～90 weight portion.
Rare ginsenoside compositions the most according to claim 1, wherein, this rare ginsenoside compositions comprises:
Ginsenoside Rg 5 20～40 weight portion,
Ginsenoside Rg3 20～40 weight portion,
Ginsenoside Rk1 20～40 weight portion.
Rare ginsenoside compositions the most according to claim 1 and 2, wherein, with in this rare ginsenoside compositions
Total ginsenoside 100 weight portion meter, described ginsenoside Rg 5, Rg3 and Rk1 add up to more than 20 weight portions.
4. according to claims 1 to 3 arbitrarily according to any one of rare ginsenoside compositions, wherein, rare relative to this
Total amount 100 weight portion of Panaxsaponin composition, described ginsenoside Rg 5, Rg3 and Rk1 add up to more than 1 weight portion.
5. according to the use in preparing antitumor drug of the rare ginsenoside compositions according to any one of Claims 1 to 4
On the way.
Purposes the most according to claim 5, wherein, described antitumor drug is peroral dosage form or injection type.
7. according to the purposes according to any one of claim 5～6, wherein, described tumor is pulmonary carcinoma, colon cancer, gastric cancer or breast
Adenocarcinoma.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610616138.3A CN106109482A (en) | 2016-07-29 | 2016-07-29 | A kind of glycol group rare ginsenoside compositions with anti-tumor activity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610616138.3A CN106109482A (en) | 2016-07-29 | 2016-07-29 | A kind of glycol group rare ginsenoside compositions with anti-tumor activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106109482A true CN106109482A (en) | 2016-11-16 |
Family
ID=57254274
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610616138.3A Pending CN106109482A (en) | 2016-07-29 | 2016-07-29 | A kind of glycol group rare ginsenoside compositions with anti-tumor activity |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106109482A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581022A (en) * | 2016-12-04 | 2017-04-26 | 西北大学 | Application of ginsenoside Rk1 to preparation of anti-tumor drugs |
| CN106727630A (en) * | 2016-12-04 | 2017-05-31 | 西北大学 | Application of the ginsenoside Rg 5 in antineoplastic is prepared |
| CN107095891A (en) * | 2017-04-28 | 2017-08-29 | 吉林加健康产业股份有限公司 | Ginseng composition and its application in treatment of vascular knurl or lymph cancer |
| CN109045053A (en) * | 2018-07-02 | 2018-12-21 | 西安巨子生物基因技术股份有限公司 | Panaxsaponin composition and the application for treating leukopenia |
| CN111184731A (en) * | 2020-01-21 | 2020-05-22 | 西安巨子生物基因技术股份有限公司 | Application of ginsenoside Rg5 in preparation of pharmaceutical composition for improving sleep |
| CN111265536A (en) * | 2020-03-31 | 2020-06-12 | 陕西巨子生物技术有限公司 | Antitumor composition containing rare ginsenoside Rk2, CK and PPT |
| CN112245443A (en) * | 2020-08-25 | 2021-01-22 | 富力 | Composition of ginsenoside Rg3 and Rg5 and its anti-tumor medicine |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1463980A (en) * | 2002-06-04 | 2003-12-31 | 中国科学院大连化学物理研究所 | Process for preparing panaxoside Rk1 and Rg5 by by panaxadiol type saponins acid hydrolysis |
| CN101244104A (en) * | 2008-03-24 | 2008-08-20 | 中国科学院长春应用化学研究所 | Method for increasing rare saponin content in panax ginseng total saponin extract |
| CN103271891A (en) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | Ginsenoside nano-micelle, and preparation method, application and pharmaceutical composition thereof |
| CN104487079A (en) * | 2012-05-25 | 2015-04-01 | 韩国科学技术研究院 | Panax spp. plant extract with increased content ratio of ginsenoside rg3, rg5, and rk1 produced by microwave irradiation, a method of preparing the panax spp. plant extract, and a composition including the panax spp. plant extract |
-
2016
- 2016-07-29 CN CN201610616138.3A patent/CN106109482A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1463980A (en) * | 2002-06-04 | 2003-12-31 | 中国科学院大连化学物理研究所 | Process for preparing panaxoside Rk1 and Rg5 by by panaxadiol type saponins acid hydrolysis |
| CN101244104A (en) * | 2008-03-24 | 2008-08-20 | 中国科学院长春应用化学研究所 | Method for increasing rare saponin content in panax ginseng total saponin extract |
| CN104487079A (en) * | 2012-05-25 | 2015-04-01 | 韩国科学技术研究院 | Panax spp. plant extract with increased content ratio of ginsenoside rg3, rg5, and rk1 produced by microwave irradiation, a method of preparing the panax spp. plant extract, and a composition including the panax spp. plant extract |
| CN103271891A (en) * | 2013-04-28 | 2013-09-04 | 福建南方制药股份有限公司 | Ginsenoside nano-micelle, and preparation method, application and pharmaceutical composition thereof |
Non-Patent Citations (1)
| Title |
|---|
| 邵志敏等: "《乳腺肿瘤学》", 30 November 2013 * |
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106581022A (en) * | 2016-12-04 | 2017-04-26 | 西北大学 | Application of ginsenoside Rk1 to preparation of anti-tumor drugs |
| CN106727630A (en) * | 2016-12-04 | 2017-05-31 | 西北大学 | Application of the ginsenoside Rg 5 in antineoplastic is prepared |
| CN107095891A (en) * | 2017-04-28 | 2017-08-29 | 吉林加健康产业股份有限公司 | Ginseng composition and its application in treatment of vascular knurl or lymph cancer |
| WO2018196537A1 (en) * | 2017-04-28 | 2018-11-01 | 吉林加一健康产业股份有限公司 | Composition for preventing and treating hemangioma or lymphoma and preparation method and use thereof |
| CN109045053A (en) * | 2018-07-02 | 2018-12-21 | 西安巨子生物基因技术股份有限公司 | Panaxsaponin composition and the application for treating leukopenia |
| CN111184731A (en) * | 2020-01-21 | 2020-05-22 | 西安巨子生物基因技术股份有限公司 | Application of ginsenoside Rg5 in preparation of pharmaceutical composition for improving sleep |
| CN111265536A (en) * | 2020-03-31 | 2020-06-12 | 陕西巨子生物技术有限公司 | Antitumor composition containing rare ginsenoside Rk2, CK and PPT |
| WO2021197372A1 (en) * | 2020-03-31 | 2021-10-07 | 陕西巨子生物技术有限公司 | Anti-tumor composition containing rare ginsenosides rk2, ck, and ppt |
| CN112245443A (en) * | 2020-08-25 | 2021-01-22 | 富力 | Composition of ginsenoside Rg3 and Rg5 and its anti-tumor medicine |
| CN116096393A (en) * | 2020-08-25 | 2023-05-09 | 大连富生天然药物开发有限公司 | Composition of ginsenoside Rg3 and Rg5 and antitumor medicines thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106109482A (en) | A kind of glycol group rare ginsenoside compositions with anti-tumor activity | |
| CN106109483A (en) | There is the glycol group/triol group rare ginsenoside compositions of anti-tumor activity | |
| CN103179967A (en) | Anti-tumor pharmaceutical composition | |
| CN102441168B (en) | Medicine composition containing apigenin, apigenin derivant and Bc1-2 inhibitor and application thereof in preparation of medicines capable of treating cancer | |
| CN103735653B (en) | A kind of Chinese medicine extract with anti-tumor activity and its production and use | |
| CN101143148B (en) | Application of paris saponin I and its derivatives | |
| CN101926844B (en) | Stellera chamaejasme L extract and anti-tumor action thereof | |
| Peng et al. | Dehydrocostus lactone inhibits the proliferation of esophageal cancer cells in vivo and in vitro through ROS-mediated apoptosis and autophagy | |
| CN108542927B (en) | Application of radix scutellariae sessiliflorae and extract thereof in anti-tumor aspect | |
| CN108452009A (en) | A kind of application including Common Leafflower Herb, rainbow conk, Radix Salviae Miltiorrhizae and the Chinese medicine composition of Asian puccoon in the drug for preparing treatment liver cancer | |
| CN106214688A (en) | A kind of rare ginsenoside compositions comprising rare ginsenoside Rg5 | |
| CN106309758B (en) | Pharmaceutical composition for resisting gastrointestinal cancer | |
| KR20200066910A (en) | Anticancer composition comprising herbal extract | |
| CN101879173B (en) | Application of Corilagin in preparing anti-tumor drugs | |
| CN106236757A (en) | A kind of rare ginsenoside compositions comprising rare Protopanaxatriol PPT | |
| CN102688228A (en) | Pharmaceutical composition containing apigenin, apigenin derivative, rubescensin and rubescensin derivative, and application thereof | |
| CN102232957B (en) | Use of 3-acetoxyl-8, 24-lanostadiene-21-acid in preparing medicines for preventing or treating liver cancer or breast cancer | |
| CN102335180B (en) | Application of ursane compounds in preparing antitumor drugs | |
| CN109223762A (en) | Glabrene is preparing the application in anticancer drug | |
| CN108272980A (en) | A kind of Qingre Xiaoji Recipe agent | |
| CN114028381B (en) | Medicine for treating ovarian cancer and application thereof | |
| CN110237081A (en) | Low polarity rare ginsenoside mixture Δ (20-21) PPD/ Δ (20-22) PPD and application thereof | |
| CN104173354B (en) | Can treating cancer pharmaceutical compositions | |
| CN109350620B (en) | A kind of drug and application thereof for treating oophoroma | |
| CN106236766A (en) | A kind of rare ginsenoside compositions comprising rare ginsenoside Rk3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161116 |